Evidence map›Paper›PMID 36357681›Full record

ArticleNature medicine2022

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.

Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jögi and 14 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 341 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
341citing papers in PubMed, 10 pooled it
62.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

341 citing papers in PubMed, 10 syntheses or guidelines pooled it, 457 citations in OpenAlex.

  1. Pooled it
  2. Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

281 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 4 countries.

Rik Ossenkoppele *Lund University, Clinical Memory Research Unit, Lund, Sweden. r.ossenkoppele@amsterdamumc.nl.ORCID http://orcid.org/0000-0003-1584-7477
Alexa Pichet Binette *Lund University, Clinical Memory Research Unit, Lund, Sweden.ORCID http://orcid.org/0000-0001-5218-3337
Colin GrootLund University, Clinical Memory Research Unit, Lund, Sweden.
Ruben SmithLund University, Clinical Memory Research Unit, Lund, Sweden.ORCID http://orcid.org/0000-0001-7147-0112
Olof StrandbergLund University, Clinical Memory Research Unit, Lund, Sweden.
Sebastian PalmqvistLund University, Clinical Memory Research Unit, Lund, Sweden.ORCID http://orcid.org/0000-0002-9267-1930
Erik StomrudLund University, Clinical Memory Research Unit, Lund, Sweden.
Pontus TidemanLund University, Clinical Memory Research Unit, Lund, Sweden.
Tomas OhlssonDepartment of Radiation Physics, Skåne University Hospital, Lund, Sweden.
Jonas JögiSkåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden.
Keith JohnsonDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Reisa SperlingDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Vincent DoreThe Australian e-Health Research Centre CSIRO Melbourne Victoria Australia, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8051-0558
Colin L MastersThe Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia, Parkville, Victoria, Australia.
Christopher RoweDepartment of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia, Melbourne, Victoria, Australia.
Denise VisserAmsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
Bart N M van BerckelAmsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-5299-3628
Wiesje M van der FlierAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-8766-6224
Suzanne BakerLawrence Berkeley National Laboratory, Berkeley, CA, USA.
William J JagustLawrence Berkeley National Laboratory, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-4458-113X
Heather J WisteDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8178-6601
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7916-622X
Oskar HanssonLund University, Clinical Memory Research Unit, Lund, Sweden. oskar.hansson@med.lu.se.ORCID http://orcid.org/0000-0001-8467-7286
Lund University · SEAmsterdam Neuroscience · NLBrigham and Women's Hospital · USFlorey Institute of Neuroscience and Mental Health · AULawrence Berkeley National Laboratory · USMayo Clinic in Arizona · USSkåne University Hospital · SECommonwealth Scientific and Industrial Research Organisation · AUMayo Clinic in Florida · US

Funding

Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2010 to 2026
$50.2M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Dissecting causal events in Alzheimer's diseaseF31AG067677 · NIA · BAYLOR COLLEGE OF MEDICINE · PI MANGLEBURG, CARL GRANT · 2020 to 2021
$84k
NIA NIH HHS F31 AG067677NIA NIH HHS P01 AG036694NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A

Indexed as

Alzheimer DiseaseAmyloidosisCognitive DysfunctionAmyloidAmyloid beta-PeptidesBiomarkersBrainHumansPlaque, AmyloidPositron-Emission Tomographytau ProteinsAmyloidAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID36357681
PMCPMC9671808
OpenAlexW4308773890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.